🇺🇸 FDA
Patent

US 9068185

Antisense modulation of nuclear hormone receptors

granted A61PA61P1/00A61P11/06

Quick answer

US patent 9068185 (Antisense modulation of nuclear hormone receptors) held by Sarepta Therapeutics, Inc. expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P1/00, A61P11/06, A61P19/02, A61P25/28